Cargando…

Short‐Term Glucocorticoid Treatment Reduces Circulating Sclerostin Concentrations in Healthy Young Men: A Randomized, Placebo‐Controlled, Double‐Blind Study

Glucocorticoid use is the most common cause of osteoporosis in young individuals. In the current study, we investigated the effects of glucocorticoid treatment on circulating sclerostin concentrations and serum bone turnover markers in healthy young men. We performed additional measurements in two c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jacobsson, Merel, van Raalte, Daniël H, Heijboer, Annemieke C, den Heijer, Martin, de Jongh, Renate T
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7422706/ https://www.ncbi.nlm.nih.gov/pubmed/32803106 http://dx.doi.org/10.1002/jbm4.10341

Ejemplares similares

Serum sclerostin is negatively associated with insulin sensitivity in obese but not lean women
por: Aznou, Anouar, et al.
Publicado: (2021)

Effect of antiretroviral therapy on bone turnover and bone mineral density in men with primary HIV-1 infection
por: Vlot, Mariska C., et al.
Publicado: (2018)

Gender‐Affirming Hormone Treatment Decreases Bone Turnover in Transwomen and Older Transmen
por: Vlot, Mariska C, et al.
Publicado: (2019)

Regulation of Circulating Sclerostin Levels by Sex Steroids in Women and in Men
por: Mödder, Ulrike IL, et al.
Publicado: (2011)

Relation of Age, Gender, and Bone Mass to Circulating Sclerostin Levels in Women and Men
por: Mödder, Ulrike I, et al.
Publicado: (2011)

Circulating sclerostin is not suppressed following a single bout of exercise in young men
por: Guerriere, Katelyn I., et al.
Publicado: (2018)

Fracture Risk in Trans Women and Trans Men Using Long‐Term Gender‐Affirming Hormonal Treatment: A Nationwide Cohort Study
por: Wiepjes, Chantal M, et al.
Publicado: (2019)

Regulation of sclerostin in glucocorticoid-induced osteoporosis (GIO) in mice and humans
por: Thiele, Sylvia, et al.
Publicado: (2019)

Circulating levels of sclerostin are associated with cardiovascular mortality
por: Novo-Rodríguez, Cristina, et al.
Publicado: (2018)

Elevated Circulating Sclerostin Concentrations in Individuals With High Bone Mass, With and Without LRP5 Mutations
por: Gregson, Celia L., et al.
Publicado: (2014)

Single Dose of SHR-1222, a Sclerostin Monoclonal Antibody, in Healthy Men and Postmenopausal Women With Low Bone Mass: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Phase I Study
por: Dai, Zhijie, et al.
Publicado: (2021)

Effect of adrenocorticotropic hormone infusion on circulating sclerostin levels
por: Zaheer, Sarah, et al.
Publicado: (2021)

Sclerostin
por: Silverman, Stuart L.
Publicado: (2010)

Associations of Serum 25(OH)D Concentrations with Lung Function, Airway Inflammation and Common Cold in the General Population
por: Rafiq, Rachida, et al.
Publicado: (2018)

Effect of high-dose glucocorticoid treatment on human brown adipose tissue activity: a randomised, double-blinded, placebo-controlled cross-over trial in healthy men
por: Maushart, Claudia Irene, et al.
Publicado: (2023)

Multiple doses of SHR-1222, a sclerostin monoclonal antibody, in postmenopausal women with osteoporosis: A randomized, double-blind, placebo-controlled, dose-escalation phase 1 trial
por: Dai, Zhijie, et al.
Publicado: (2023)

Circulating bioactive sclerostin levels in an Austrian population-based cohort
por: Kerschan-Schindl, Katharina, et al.
Publicado: (2021)

The Role of Estrone in Feminizing Hormone Treatment
por: Tebbens, Marieke, et al.
Publicado: (2021)

Anti-Sclerostin Antibody Inhibits Internalization of Sclerostin and Sclerostin-Mediated Antagonism of Wnt/LRP6 Signaling
por: van Dinther, Maarten, et al.
Publicado: (2013)

The Measurement and Interpretation of Fibroblast Growth Factor 23 (FGF23) Concentrations
por: Heijboer, Annemieke C., et al.
Publicado: (2022)

Multiple Sclerosis Patients Show Lower Bioavailable 25(OH)D and 1,25(OH)(2)D, but No Difference in Ratio of 25(OH)D/24,25(OH)(2)D and FGF23 Concentrations
por: Vlot, Mariska C, et al.
Publicado: (2019)

Circulating sclerostin is associated with bone mineral density independent of HIV-serostatus
por: Ross, Ryan D., et al.
Publicado: (2020)

Circulating Levels of Sclerostin Predict Glycemic Improvement after Sleeve Gastrectomy
por: Carbone, Federico, et al.
Publicado: (2021)

l‐carnitine downregulate the muscle wasting effect of glucocorticoids in pemphigus patient: A randomized double‐blind placebo‐controlled study
por: Noormohammadi, Zeinab, et al.
Publicado: (2023)

Sclerostin activity plays a key role in the negative effect of glucocorticoid signaling on osteoblast function in mice
por: Beier, Eric E, et al.
Publicado: (2017)

Trabecular bone score and sclerostin concentrations in patients with primary adrenal insufficiency
por: Zdrojowy-Wełna, Aleksandra, et al.
Publicado: (2022)

Influence of Muscle Mass and Strength on Bone Mineralisation with Consideration of Sclerostin Concentration
por: Patalong-Wójcik, Martyna, et al.
Publicado: (2023)

Herbo-mineral supplementation in men with idiopathic oligoasthenoteratospermia : A double blind randomized placebo-controlled trial
por: Kumar, Rajeev, et al.
Publicado: (2011)

Tacrolimus in the treatment of myasthenia gravis in patients with an inadequate response to glucocorticoid therapy: randomized, double-blind, placebo-controlled study conducted in China
por: Zhou, Lei, et al.
Publicado: (2017)

Correction to “L‐carnitine downregulate the muscle wasting effect of glucocorticoids in pemphigus patient: A randomized double‐blind placebo‐controlled study”
Publicado: (2023)

The Effect of Renal Dysfunction on Circulating Sclerostin Level in Patients with Type 2 Diabetes
por: Kim, Se Hwa, et al.
Publicado: (2014)

Circulating Sclerostin and Irisin Are Related and Interact with Gender to Influence Adiposity in Adults with Prediabetes
por: Klangjareonchai, Theerawut, et al.
Publicado: (2014)

Circulating levels of sclerostin but not DKK1 associate with laboratory parameters of CKD-MBD
por: Behets, Geert J., et al.
Publicado: (2017)

The association of circulating sclerostin level with markers of bone metabolism in patients with thyroid dysfunction
por: Mihaljević, Olgica, et al.
Publicado: (2020)

Sclerostin and Vascular Pathophysiology
por: Catalano, Antonino, et al.
Publicado: (2020)

Sclerostin and Cardiovascular Disease
por: Tobias, Jonathan H.
Publicado: (2023)

The When, What & How of Measuring Vitamin D Metabolism in Clinical Medicine
por: Dirks, Niek F., et al.
Publicado: (2018)

Randomized, Double-Blinded, Placebo-Controlled Trial of Fibrinogen Concentrate Supplementation After Complex Cardiac Surgery
por: Ranucci, Marco, et al.
Publicado: (2015)

Treatment with cinacalcet increases plasma sclerostin concentration in hemodialysis patients with secondary hyperparathyroidism
por: Kuczera, Piotr, et al.
Publicado: (2016)

A parallel, randomized, double-blind, placebo-controlled study to investigate the effect of SagaPro on nocturia in men
por: Sigurdsson, Steinthor, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_g6b1ouec74jig85pvfi6vmsm32